glp-1 news today oct 2 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care Understanding GLP-1s and their dynamic

She provides clients with timely analysis of FDA regulations, policies, and guidance documents and strategic advice on FDA engagement regarding compliance-focused issues and good practice standards for FDA-regulated products

On the negative side, the rush to capitalize on the GLP-1 trend has attracted companies with limited supplement expertise, questionable ingredient sourcing, and inflated marketing claims

Liquid calories are easier to tolerate, but they also go down fast and may not keep you full for long

Let's dive in

Novo Nordisk is the market leader: Ozempic (weekly injection for type 2 diabetes) Wegovy (higher-dose weekly injection for obesity) Rybelsus ( Oral tablets for diabetes Oral tablets for weight management is in phase 3 trials) Eli Lilly is the other major player: Mounjaro (weekly injection for type 2 diabetes) Zepbound (higherdose weekly injection for obesity) This duopoly meant that both stocks had an incredible run-up from 2020 to 2024